Becton Dickinson and (NYSE:BDX) had its price target upped by equities researchers at Raymond James from $265.00 to $288.00 in a research note issued on Friday, June 28th, Stock Target Advisor reports. The firm presently has a “strong-buy” rating on the medical instruments supplier’s stock. Raymond James’ price target indicates a potential upside of 14.81% from the company’s current price.
Other equities research analysts also recently issued research reports about the company. BMO Capital Markets increased their price target on Sun Life Financial from C$58.00 to C$60.00 in a research report on Friday, May 10th. ValuEngine upgraded Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. Morgan Stanley upped their target price on Wynn Resorts from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Friday, May 10th. Barclays cut Buckeye Partners from an “overweight” rating to an “equal weight” rating in a research note on Monday, May 13th. Finally, UBS Group set a $133.00 target price on LHC Group and gave the stock a “buy” rating in a research note on Friday, May 10th. Five equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $263.58.
NYSE BDX traded down $2.99 during trading on Friday, reaching $250.84. 758,995 shares of the company’s stock were exchanged, compared to its average volume of 924,318. The firm’s 50 day simple moving average is $245.44. The firm has a market capitalization of $68.47 billion, a PE ratio of 22.78, a P/E/G ratio of 1.88 and a beta of 1.12. The company has a quick ratio of 0.59, a current ratio of 0.96 and a debt-to-equity ratio of 0.82. Becton Dickinson and has a fifty-two week low of $208.62 and a fifty-two week high of $265.87.
In other Becton Dickinson and news, EVP Betty D. Larson sold 1,700 shares of the stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $224.97, for a total transaction of $382,449.00. Following the completion of the sale, the executive vice president now directly owns 11,493 shares in the company, valued at approximately $2,585,580.21. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Patrick Kaltenbach sold 275 shares of the stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $235.00, for a total value of $64,625.00. Following the sale, the executive vice president now owns 16,482 shares of the company’s stock, valued at $3,873,270. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 21,154 shares of company stock valued at $4,955,775. Company insiders own 0.12% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Sageworth Trust Co acquired a new stake in shares of Becton Dickinson and in the 2nd quarter valued at about $545,000. Pioneer Trust Bank N A OR grew its stake in shares of Becton Dickinson and by 6.2% in the 2nd quarter. Pioneer Trust Bank N A OR now owns 14,428 shares of the medical instruments supplier’s stock valued at $3,636,000 after buying an additional 840 shares during the period. JGP Global Gestao de Recursos Ltda. acquired a new stake in shares of Becton Dickinson and in the 2nd quarter valued at about $1,088,000. Black Diamond Financial LLC acquired a new stake in shares of Becton Dickinson and in the 2nd quarter valued at about $562,000. Finally, Davy Asset Management Ltd acquired a new stake in shares of Becton Dickinson and in the 2nd quarter valued at about $354,000. Institutional investors own 84.54% of the company’s stock.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Recommended Story: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.